OncoMed Pharmaceuticals, Inc. (OMED)

Oncology Corporate Profile

Stock Performance

9.4900
0.0000

HQ Location

800 Chesapeake Drive
Redwood City, CA 94063

Company Description

OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel therapeutics targeting cancer stem cells (CSCs). OncoMed has six anti-cancer product candidates in clinical development, the most advanced of which are in randomized Phase 2 clinical trials. Demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), brontictuzumab (anti-Notch1, OMP-52M51), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), and ipafricept (FZD8-Fc, OMP-54F28) each target key cancer stem cell signaling pathways including Notch and Wnt. OncoMed plans to file an Investigational New Drug application in early 2015 for anti-RSPO3 (OMP-131R10), an antibody targeting a third key cancer stem cell signaling pathway called R-spondin-LGR. OncoMed is also pursuing discovery of additional novel anti-CSC and cancer immune-oncology product candidates. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK).

Website: http://www.oncomed.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
demcizumabanti-DLL4 monoclonal antibody (humanized)1st line metastatic Colorectal cancerII
demcizumab (+ carboplatin and pemetrexed)anti-DLL4 monoclonal antibody (humanized)1st line metastatic Non Small Cell Lung Cancer (NSCLC)II
demcizumabanti-DLL4 monoclonal antibody (humanized)2nd line metastatic Colorectal cancerII
tarextumab / OMP-59R5monoclonal antibody anti-notch receptorPancreatic cancerII
demcizumab (+ paclitaxel and gemcitabine)anti-DLL4 monoclonal antibody (humanized)Pancreatic cancerII
demcizumab (+ paclitaxel)anti-DLL4 monoclonal antibody (humanized)Platinum-sensitive Ovarian cancerII
tarextumab / OMP-59R5monoclonal antibody anti-notch receptorSmall Cell Lung Cancer (SCLC)II
ipafricept / OMP-54F28 (+ nab-paclitaxel and gemcitabine)anti-cancer stem cell antibodyPancreatic cancerI
vantictumab / OMP-18R5WNT-pathway targeting antibodyVarious cancer typesI
OMP-385B83anti-DLL4 monoclonal antibody (humanized)Various cancer typesI
brontictuzumabNOTCH-1 inhibitorVarious cancer typesI
OMP-131R10anti-RSPO3 antibodyVarious cancer typesI
demcizumab (+ pembrolizumab)anti-DLL4 monoclonal antibody (humanized)Various cancer typesI

View additional information on product candidates here »

Pipeline image

Source


http://www.oncomed.com/index.html

Recent News Headlines

OncoMed Pharmaceuticals Completes Enrollment of Phase 2 YOSEMITE Clinical Trial of Demcizumab in Pancreatic Cancer

9/1/2016 11:13 am

(Yahoo! Finance) Sept 1, 2016 - OncoMed Pharmaceuticals Inc. today announced the completion of patient enrollment of 207 patients in the randomized Phase 2 "YOSEMITE" clinical trial of demcizumab (anti-DLL4, OMP-21M18) for the treatment of first-line metastatic pancreatic cancer. Topline results are expected in the first half of 2017.

Guardant Health Collaborates with OncoMed Pharmaceuticals on Anti-RSPO3 Clinical Trial

7/15/2016 10:51 am

(Yahoo! Finance) July 14, 2016 - Guardant Health announced a strategic collaboration with OncoMed Pharmaceuticals. Using Guardant Health's digital sequencing technology, the companies have developed a custom blood test that looks for specific biomarkers relevant to OncoMed's ongoing Phase 1a/1b trial of its anti-RSP03 antibody (OMP-131R10).

OncoMed Presents Phase 1b Data for First-in-Class Treatments in Ovarian, Breast and Lung Cancer at the 2016 ASCO Annual Meeting

6/5/2016 06:23 pm

(NASDAQ) June 5, 2016 - Presentations included the first Phase 1b combination data for OncoMed's Wnt pathway inhibitors, ipafricept (FZD8-Fc, OMP-54F28) in recurrent platinum-sensitive ovarian cancer and vantictumab (anti-Fzd7, OMP-18R5) in Her2-negative breast cancer.

Hepatitis C Deaths Hit All-Time High in United States

5/5/2016 11:04 am

(CNN) May 4, 2016 - Hepatitis C-related deaths reached an all-time high in 2014, the Centers for Disease Control and Prevention announced Wednesday, surpassing total combined deaths from 60 other infectious diseases including HIV, pneumococcal disease and tuberculosis.

OncoMed Presents Biomarker Research for Two Clinical Programs and Demcizumab Mechanism Data at the AACR Annual Meeting 2016

4/20/2016 12:01 pm

(PM360) Apr 20, 2016 - OncoMed Pharmaceuticals Inc. presented new biomarker research associated with its clinical programs for anti-RSPO3 (OMP-131R10) and vantictumab (anti-FZD7, OMP-18R5), as well as new preclinical mechanism-of-action data for demcizumab (anti-DLL4, OMP-18M21), at the American Association of Cancer Research (AACR) Meeting.

European Medicines Agency Validates Bristol-Myers Squibb’s Application for Opdivo® (nivolumab) for the Treatment of Classical Hodgkin Lymphoma Patients

3/31/2016 07:00 am

(BMS) Mar 30, 2016 - Bristol-Myers Squibb Company announced today that the European Medicines Agency (EMA) validated a type II variation application, which seeks to extend the current indications for Opdivo to include the treatment of patients with classical Hodgkin lymphoma (cHL) after prior therapies.

OncoMed Initiates Phase 1b Immuno-Oncology Combination Clinical Trial for Demcizumab and Pembrolizumab (anti-PD1)

3/17/2016 11:19 am

(StreetInsider) Mar 17, 2016 - OncoMed Pharmaceuticals, Inc. today announced dosing of the first patient in its Phase 1b clinical trial of OncoMed’s investigational agent demcizumab (anti-DLL4, OMP-21M18), with Merck’s anti-Programmed Cell Death 1 (PD1) therapy pembrolizumab (KEYTRUDA®).

OncoMed Presents Updated Phase 1b Data for Tarextumab in Small Cell Lung Cancer

2/22/2016 11:43 am

(TheStreet) Feb 22, 2016 - Higher doses of tarextumab appear to correlate with improved progression-free and overall survival.

OncoMed Provides Update on Tarextumab Phase 2 Programs

2/8/2016 12:04 pm

(PipelineReview.com) Feb 8, 2016 - Phase 2 PINNACLE study in small cell lung cancer continues following DSMB and FDA review.

OncoMed Shares Fall After Discouraging News on Pancreatic Cancer Drug

1/25/2016 11:18 am

(Xconomy San Francisco) Jan 25, 2016 - OncoMed Pharmaceuticals said this morning that an independent data safety monitoring board took a look at the interim data from an ongoing Phase 2 trial of its experimental drug for pancreatic cancer, tarextumab, and the results weren’t good.

OncoMed Presents Updated Phase 1b Data for Demcizumab in First-Line Pancreatic Cancer at the Gastrointestinal Cancers Symposium

1/22/2016 11:15 am

(StreetInsider) Jan 22, 2016 - OncoMed Pharmaceuticals Inc., a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, announced updated survival data from the company’s Phase 1b clinical trial of demcizumab (anti-DLL4, OMP-21M18) at the Gastrointestinal Cancers Symposium.

OncoMed Enrolls First Patient in Phase 1b Anti-RSPO3 Tria

1/11/2016 11:29 am

(Morningstar) Jan 11, 2016 - OncoMed Pharmaceuticals Inc., a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced that the first patient has been enrolled and dosed in the Phase 1b portion of the Phase 1a/1b clinical trial of anti-RSPO3 (OMP-131R10).

Medicare Proposes New Coverage Policy for Stem Cell Transplant for Sickle Cell, Myelofibrosis, and Myeloma

11/17/2015 12:03 pm

(ASH) Nov 12, 2015 - On October 29, 2015, the Centers for Medicare and Medicaid Services (CMS) released a new proposed coverage policy for hematopoietic stem cell transplant for Medicare patients.

Ready for Profound Reimbursement Changes? Read the New ASCO in Action Brief on MACRA

11/17/2015 12:03 pm

(ASCO in Action) Nov 16, 2015 - The Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) introduced significant changes, on an ambitious timeline, to how Medicare will pay oncologists for the care they provide—and now is the time to understand and prepare for these changes.

AstraZeneca's Tagrisso To Cost $12,750 For A Month's Supply

11/17/2015 12:02 pm

(Reuters) Nov 17, 2015 - AstraZeneca's new lung cancer pill Tagrisso, which won early U.S. approval on Friday, will cost $12,750 for a month's supply.

Tagrisso™ (osimertinib) Approved for Advanced Lung Cancer, Available Immediately at Biologics, Inc.

11/17/2015 12:02 pm

(Yahoo! Finance) Nov 17, 2015 - Biologics, Inc., is pleased to announce that it has been selected by AstraZeneca as a specialty pharmacy provider for Tagrisso (osimertinib). Tagrisso was designated as a Breakthrough Therapy by the U.S. Food and Drug Administration, and was approved on November 13, 2015, for the treatment of advanced lung cancer.

Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy

11/17/2015 12:01 pm

(Georgia Tech) Nov 17, 2015 - Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.

Deeper Grasp of Chemotherapy-Induced Peripheral Neuropathy

11/17/2015 12:01 pm

(Medscape Medical News) Nov 12, 2015 - Two unrelated studies, both published in the Journal of Clinical Oncology, provide deeper insights into peripheral neuropathy — a disabling side effect experienced by patients on many chemotherapy regimens, particularly regimens containing oxaliplatin (Eloxatin, sanofi-aventis) and paclitaxel (multiple brands).

Nondrug Interventions Improve Quality Of Life For Chinese Cancer Patients

11/17/2015 12:01 pm

(University Of Illinois At Urbana-Champaign) Nov 17, 2015 - A meta-analysis of dozens of studies of traditional Chinese medicine and other nonpharmacological interventions meant to improve patients' quality of life affirms that these approaches, on the whole, help alleviate depression, fatigue, pain, anxiety, insomnia and gastrointestinal problems in Chinese cancer patients.

New Studies Investigating the Use of KEYTRUDA® (pembrolizumab) Across Solid and Hematological Cancers to Be Presented at Upcoming Congresses

11/17/2015 12:01 pm

(Merck) Nov 17, 2015 - Merck, known as MSD outside the United States and Canada, today announced that data investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in advanced non-small cell lung cancer, melanoma, classical Hodgkin lymphoma, multiple myeloma, and ER-positive/HER2-negative breast cancer will be presented at four medical congresses through the end of this year.

Amgen to Present IMLYGIC (Talimogene Laherparepvec) Data at the 2015 International Congress of the Society for Melanoma Research

11/17/2015 12:01 pm

(Amgen) Nov 16, 2015 - Highlights include analyses from pivotal study and new data from phase 1b combination trial in metastatic melanoma.

Novocure Announces 18 Presentations on Tumor Treating Fields at SNO 2015 Including New Analyses of the EF-14 Newly Diagnosed Glioblastoma Clinical Trial Data

11/17/2015 12:01 pm

(TheStreet) Nov 17, 2015 - Quality of life was maintained throughout treatment with Tumor Treating Fields; EF-14 patients who continued Tumor Treating Fields concurrent with second-line chemotherapy at first recurrence of glioblastoma lived significantly longer than patients who received chemotherapy alone.

Cerulean Announces Clinical Collaboration with AstraZeneca and the National Cancer Institute to Evaluate the Combination of LYNPARZA™ and CRLX101

11/17/2015 12:01 pm

(Yahoo! Finance) Nov 17, 2015 - Three-party collaboration will explore synergies between AstraZeneca’s leading PARP inhibitor and Cerulean’s topoisomerase inhibitor.

Executive View - FDA Approval Is Single Biggest Genmab Moment - CEO

11/17/2015 12:01 pm

(Reuters) Nov 17, 2015 - Danish biotech firm Genmab GEN.CO said late on Monday the U.S. Food and Drug Administration had approved its cancer treatment Darzalex (daratumumab) for blood cancer multiple myeloma.

UK Researchers Develop Pancreatic Cancer Treatment ‘Breakthrough’

11/17/2015 12:00 pm

(PharmaTimes [UK]) Nov 17, 2015 - Ulster University has developed a pioneering treatment for pancreatic cancer, which researchers are hailing as the first breakthrough in over 40 years that could significantly boost survival rates.

Nanotech-based Sensor Developed To Measure MicroRNAS In Blood, Speed Cancer Detection

11/17/2015 12:00 pm

(Indiana University-Purdue University Indianapolis) Nov 17, 2015 - A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.

Pre-Op Blood Tests May Predict Post-Op Morbidity in Ovarian CA

11/17/2015 12:00 pm

(Physician’s Briefing/HealthDay News) Nov 16, 2015 - Pre-op thrombocytosis, leukocytosis tied to post-op morbidity; increased mortality for patients with both.

OncoMed Pharmaceuticals Announces Presentation of Tarextumab Small Cell Lung Cancer Data at the 16th World Conference on Lung Cancer

9/9/2015 10:47 am

(StreetInsider) Sept 9, 2015 - OncoMed Pharmaceuticals Inc. reported new biomarker and updated clinical data for the company's Phase 2 anti-Notch2/3 therapeutic candidate, tarextumab (OMP-59R5).

OncoMed Pharmaceuticals Completes Enrollment of Phase 2 ALPINE Clinical Trial of Tarextumab in Pancreatic Cancer

8/31/2015 10:51 am

(StreetInsider) Aug 31, 2015 - OncoMed Pharmaceuticals Inc. today announced that it has completed patient enrollment in its Phase 2 "ALPINE" clinical trial of tarextumab (anti-Notch2/3, OMP-59R5) for the treatment of pancreatic cancer more than eight months ahead of schedule.

Indoor Tanning Rates Dropping

7/8/2015 11:04 am

(Fox News/Reuters) July 8, 2015 - Use of indoor tanning is on the decline, according to a new study from the Centers for Disease Control and Prevention (CDC) and the National Cancer Institute.

OncoMed Presents Phase 1b Clinical Trial Data for Tarextumab in Small Cell Lung Cancer at the 2015 ASCO Annual Meeting

6/1/2015 06:26 pm

(TheStreet) June 1, 2015 - OncoMed Pharmaceuticals Inc. presented new survival and biomarker data and updated clinical response and safety results from its Phase 1b clinical trial of tarextumab (anti-Notch2/3, OMP-59R5) in patients with first-line extensive-stage small cell lung cancer at the 2015 ASCO Annual Meeting.

OncoMed Presents Updated Demcizumab Data in Non-Small Cell Lung Cancer at the 2015 ASCO Annual Meeting

6/1/2015 06:26 pm

(CNN Money) June 1, 2015 - At the 2015 ASCO Annual Meeting, OncoMed Pharmaceuticals Inc. presented data from a Phase 1b study open-label trial of demcizumab plus carboplatin and pemetrexed (Alimta(R)) in patients with first-line advanced stage non-small cell lung cancer (NSCLC).

OncoMed Presents Data From Phase 1b Trial of Demcizumab in Pancreatic Cancer at the 2015 ASCO Annual Meeting

6/1/2015 06:23 pm

(TheStreet) June 1, 2015 - At the 2015 ASCO Annual Meeting, OncoMed Pharmaceuticals Inc. presented data from its Phase 1b clinical trials of demcizumab (anti DLL4, OMP-21M18) in advanced pancreatic patients who have not received prior treatment for locally advanced or metastatic disease.

Opdivo (nivolumab) Demonstrates Superior Survival Compared to Standard of Care (docetaxel) for Previously-Treated Squamous Non-Small Cell Lung Cancer in Phase III Trial

5/31/2015 06:05 pm

(BMS) May 31, 2015 - Bristol-Myers Squibb Company today announced results from CheckMate -017, a Phase III, open-label, randomized study evaluating Opdivo (n=135) versus docetaxel (n=137) in previously treated patients with advanced squamous non-small cell lung cancer.

Penn Medicine Study Reveals Why Almost Half of At-Risk Patients Opt Out of Comprehensive Multiplex Cancer Screening

5/7/2015 12:00 pm

(Penn Medicine) May 7, 2015 - Some at-risk patients opted out of comprehensive cancer gene screening when presented with the opportunity to be tested for the presence of genes linked to various cancers, according to a recent study led by researchers at the Perelman School of Medicine at the University of Pennsylvania and the Basser Center for BRCA in Penn’s Abramson Cancer Center.

Walking Improves Mood, Boosts Energy in Cancer Survivors

4/24/2015 11:01 am

(Medscape Medical News) Apr 23, 2015 - Two studies, one from Europe and one from the United States, advise cancer survivors to be physically active to reduce adverse effects from chemotherapy and improve their health-related quality of life (HRQOL).

OncoMed Presents Demcizumab Data From Phase 1b Clinical Trial in Non-Small Cell Lung Cancer Patients at the European Lung Cancer Conference

4/16/2015 12:04 pm

(Yahoo! Finance) Apr 16, 2015 - OncoMed Pharmaceuticals Inc. presented new data from the Phase 1b clinical trial of demcizumab (anti-DLL4, OMP-21M18) in patients with first-line advanced non-small cell lung cancer (NSCLC) at the European Lung Cancer Conference.

Researchers Find Protein That May Signal More Aggressive Prostate Cancers

4/13/2015 11:04 am

(University of Michigan) Apr 13, 2015 - University of Michigan researchers have discovered a biomarker that may be a potentially important breakthrough in diagnosing and treating prostate cancer.

Study Backs HPV Vaccine for Boys

4/13/2015 07:00 am

(Toronto Star) Apr 13, 2015 - Vaccinating boys against the human papillomavirus could help reduce throat cancers and save millions, says study in journal Cancer.

Many Head and Neck Cancer Survivors Don't Return to Work

4/10/2015 12:02 pm

(Physician's Briefing/HealthDay News) Apr 9, 2015 - Many head and neck cancer survivors do not return to work, according to a study published in the April issue of Head & Neck.

OncoMed and Lilly Enter Clinical Supply Agreement to Evaluate the Combination of Demcizumab and Alimta(R) (pemetrexed for injection) in Lung Cancer

4/2/2015 12:01 pm

(OncoMed) Apr 2, 2015 - OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, announced today that it has entered into an agreement with Eli Lilly and Company.

Most Women With Early-Stage Breast Cancer Avoid Extensive Lymph Node Removal, Showing Increasing Adherence to Scientific Evidence That a Radical Operation Is No Longer Necessary

3/27/2015 11:01 am

(American College of Surgeons) Mar 26, 2015 - A new study of women with early-stage breast cancer finds that surgeons no longer universally remove most of the lymph nodes in the underarm area when a biopsy of the nearby lymph nodes shows cancer--a major change in breast cancer management.